In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma  by Mir, Shahryar E. et al.
Cancer Cell
ArticleIn Silico Analysis of Kinase Expression
Identifies WEE1 as a Gatekeeper
against Mitotic Catastrophe in Glioblastoma
Shahryar E. Mir,1,7 Philip C. De Witt Hamer,1,7 Przemek M. Krawczyk,2 Leonora Balaj,1 An Claes,5 Johanna M. Niers,1,6
Angela A.G. Van Tilborg,2 Aeilko H. Zwinderman,4 Dirk Geerts,3 Gertjan J.L. Kaspers,1 W. Peter Vandertop,1
Jacqueline Cloos,1 Bakhos A. Tannous,6 Pieter Wesseling,5 Jacob A. Aten,2 David P. Noske,1 Cornelis J.F. Van Noorden,2
and Thomas Wu¨rdinger1,6,*
1Neuro-oncology Research Group, Departments of Neurosurgery and Pediatric Oncology/Hematology, VU University Medical Center,
1081 HV, Amsterdam, the Netherlands
2Department of Cell Biology and Histology
3Department of Human Genetics
4Department of Clinical Epidemiology and Biostatistics
Academic Medical Center, University of Amsterdam, 1100 DD, Amsterdam, the Netherlands
5Department of Pathology, Radboud University Nijmegen Medical Centre, 6525 GA, Nijmegen, the Netherlands
6Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown,
MA 02113, USA
7These authors contributed equally to this work
*Correspondence: t.wurdinger@vumc.nl
DOI 10.1016/j.ccr.2010.08.011SUMMARYKinases execute pivotal cellular functions and are therefore widely investigated as potential targets in
anticancer treatment. Here we analyze the kinase gene expression profiles of various tumor types and reveal
thewee1 kinase to be overexpressed in glioblastomas.We demonstrate thatWEE1 is amajor regulator of the
G2 checkpoint in glioblastoma cells. Inhibition of WEE1 by siRNA or small molecular compound in cells
exposed to DNA damaging agents results in abrogation of the G2 arrest, premature termination of DNA repair,
and cell death. Importantly, we show that the small-molecule inhibitor of WEE1 sensitizes glioblastoma to
ionizing radiation in vivo. Our results suggest that inhibition of WEE1 kinase holds potential as a therapeutic
approach in treatment of glioblastoma.INTRODUCTION
Glioblastoma (GBM) is one of the most aggressive human
cancers and the most common primary brain tumor. The median
survival of GBM patients is <15 months because this tumor is
inherently resistant to conventional therapy (Stupp et al., 2009).
Although the conventional treatment with surgery, irradiation
(IR), and temozolomide (TMZ) postpones tumor progression
and extends patients survival to some extent, these tumors
universally recur and unrelentingly result in patient death.
Despite recent advances in understanding the underlyingSignificance
The resistance of glioblastoma cells to irradiation and chemot
ment-induced DNA damage during the G2 cell-cycle arrest. M
halt cancer cell division. Here, we inhibit the WEE1 kinase, a ga
glioblastoma cells through theG2 arrest phase and thereby indu
in extensive cytotoxicity in vitro and, more importantly, erad
adverse side effects. Therefore, manipulation of WEE1 acti
approach for glioblastoma treatment.
244 Cancer Cell 18, 244–257, September 14, 2010 ª2010 Elsevier Inmolecular mechanisms, there has been little improvement in
clinical outcome (Wen and Kesari, 2008).
Manipulation of oncogenic kinase activity has become a thera-
peutic concept in human cancer because kinases regulate
crucial cellular functions such as proliferation, apoptosis, cell
metabolism, migration, DNA damage repair, and responses to
the microenvironment (Manning et al., 2002). Several human
cancers are considered to be kinase-driven (Weinstein, 2002;
Krause and Van Etten, 2005), and inhibitors of several cancer-
driving kinases are under evaluation as potential therapeutic
agents (Cohen, 2002; Vieth et al., 2005). Most of these inhibitorsherapy is partly due to their proficient ability to repair treat-
any kinase inhibitors intend to prolong cell-cycle arrest to
tekeeper of the DNA damage-induced G2 arrest, ‘‘pushing’’
cingmitotic catastrophe and cell death. This strategy results
ication of irradiated brain tumors in mice, without showing
vity may prove therapeutically attractive as a sensitizing
c.
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Figure 1. Kinase Expression Profiles of
Cancer Data Sets
(A) Heatmap of percentile fold change of gene
expression of kinases (rows) in cancer data sets
(columns). Number of normal tissue samples (N)
and cancer samples (C) per data set are shown.
(B) Selected list of kinases expressed in various
types of cancer. Number of normal tissue samples
(N) and cancer samples (C) per data set are shown.
Percentile fold change values as in color legend,
missing values in white. P.F.C., percentile fold
change.
See also Figure S1, Table S1, and Table S2.
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WEE1 Protects GBM against Mitotic Catastropheaim at stagnation of tumor growth by interrupting the replicative
cycle of cancer cells. Examples include inhibitors of epidermal
growth factor receptor (EGFR), polo-like kinase 1 (PLK1), v-akt
murine thymoma viral oncogene homologue (AKT), mitogen-
activated protein kinase (MAPK), protein kinase C (PKC),
vascular endothelial growth factor receptor (VEGFR), and
platelet-derived growth factor receptor (PDGFR) (reviewed by
Zhang et al., 2009). These therapeutic kinase targets are mainly
deregulated by either mutation, protein fusion or gene overex-
pression (Krause and Van Etten, 2005). Thus far, results from
clinical trials testing the efficacy of kinase inhibitors in patients
with GBM have been disappointing (Omuro et al., 2007;
De Witt Hamer, 2010).
In this study we focused on the kinase gene expression profile
of GBM using publicly available gene expression data sets to
identify additional putative therapeutic targets.
RESULTS
In Silico Analysis of Microarray Data Identifies
Cancer-Specific Kinase Expression Profiles
To identify kinase targets, we used a cancer-wide approach and
selected 34 cancer-versus-normal data sets (Table S1 available
online), including two GBM data sets obtained by different
microarray platforms in distinct laboratories (Bredel et al.,Cancer Cell 18, 244–257, Se2005; Kotliarov et al., 2006). Two param-
eters of gene expression were deter-
mined, details of which are described in
Supplemental Experimental Procedures.
First, to compare the differential kinase
gene expression of cancer-versus-
normal samples among data sets, the
fold change was determined for all genes
within a data set. Then, the percentile of
fold change was determined for each
kinase within a data set to relate its
expression value to all genes in that
data set. This allowed comparison of
expression levels of each kinase between
data sets. Second, to compare the fre-
quency at which overexpression occurs
in cancer samples between data sets,
the frequency of overexpression was
determined for each kinase within eachcancer-versus-normal data set. To recover the human kinome
from the genes present in the data sets, the Entrez GeneIDs of
the human protein kinase family (518 kinases) and the human
lipid kinase family (33 kinases) were retrieved (Figures 1A,
Figure S1, and Table S2) (Manning et al., 2002; Peri et al.,
2003). The vast majority of kinase genes were represented on
the microarray platforms (Table S1 and Table S2). We found
distinct kinase expression profiles in various cancer types
(Figure 1A). Thus, potential therapeutic targets overexpressed
in a specific type of cancer may not necessarily be valid in other
cancer types.
To validate our approach, we selected kinases previously
demonstrated to be overexpressed in specific cancers and
determined their expression across our kinase profiles
(Figure 1B). Our analysis revealed v-kit Hardy-Zuckerman 4
feline sarcoma viral oncogene homolog (kit) to be selectively
overexpressed in seminomas and gastrointestinal stromal
tumors, which show clinical response to anti-KIT treatment
(Pedersini et al., 2007; Demetri et al., 2002). Moreover, egfr
overexpression was confirmed in head and neck cancers, non-
small cell lung cancers, and renal cell cancers, for which anti-
EGFR treatment can prolong overall survival (Lynch et al.,
2004; Agulnik et al., 2007; Ravaud et al., 2008).
Although we retrieved the kinase expression profiles of several
tumor types, our prime focus was to identify potentialptember 14, 2010 ª2010 Elsevier Inc. 245
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Figure 2. Glioblastoma-Specific Kinases
Heatmaps of percentile fold change gene expres-
sion (A) and frequency of overexpression (B) of
nine glioblastoma-specific kinases (rows) in data
sets (columns). F.O.E., frequency of overexpres-
sion; P.F.C., percentile fold change.
See also Table S3 and Table S4.
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WEE1 Protects GBM against Mitotic Catastrophetherapeutic targets in glioblastoma. We considered overexpres-
sion at a level surpassing 95% of all genes in a data set as sub-
stantial. Additionally, we considered overexpression in >20% of
the patient population as frequent. A listing of nine kinases was
obtained that were both substantially (Figure 2A) and frequently
(Figure 2B) overexpressed in the two available GBM data sets. In
previous investigations four of these nine selected kinases,
aurora kinase A (aurka) (Klein et al., 2004), egfr (Nicholas et al.,
2006), maternal embryonic leucine zipper kinase (melk) (Nakano
et al., 2008), and cyclin-dependent kinase 1 (cdc2) (Hodgson
et al., 2009), were described as relevantly overexpressed in
human GBM samples, emphasizing the biological plausibility of
our results. The other five kinases were not previously associ-
ated with human GBM. pdgfr, kinase insert domain receptor
(kdr), fms-related tyrosine kinase 4 (flt4), transforming growth
factor, beta receptor 1 (tgfbr1), and transforming growth factor,
beta receptor 2 (tgfbr2) had been described to be overexpressed246 Cancer Cell 18, 244–257, September 14, 2010 ª2010 Elsevier Inc.in GBM (Rich and Bigner, 2004) but they
were not included in our list. Despite
marked overexpression in the two GBM
data sets (Table S3 and Table S4), these
kinases did not meet our selection
criteria. Given the noise levels in microar-
ray data, we preferred high specificity
over sensitivity.
wee1 mRNA and Protein Are
Overexpressed in GBM and Its
Expression Level Correlates
with Survival
The individual data for the nine overex-
pressed kinases retrieved from the GBM
studies is presented in Figures 3A and
3B and Figure S2, according to glioma
grade and histological subtype. To vali-
date the results obtained in silico, we
determined mRNA expression of these
kinases in GBM cell lines and primary
samples of GBM and normal brain using
quantitative reverse transcription poly-
merase chain reaction (RT-PCR) (Fig-
ure 3C, Table S5, and Table S6).
Because WEE1 kinase plays an impor-
tant role in controlling the cell-cycle
progression (Russell and Nurse, 1987)
and because it topped the ranking of
overexpressed kinases (Figure 2, Fig-
ure 3, and Figure S2), we further studied
its role in GBM. We first determined the
levels of WEE1 protein expression innormal brain and GBM tissue sections using immunohistochem-
istry. Consistent with the gene expression data, GBM cell nuclei
contained high levels of WEE1 protein, as compared to non-
neoplastic brain regions (Figure 3D).
We then investigated the correlation between wee1 mRNA
level and patient survival using published data from 267 GBM
patients (Lee et al., 2008). Expression of wee1 was classified
as high or low, based onwhether the values were above or below
the median wee1 expression levels, respectively. This showed
high tumor wee1 expression to be significantly correlated with
worse patient survival (log rank p < 0.0059), patients with high
wee1-expressing GBM had a median survival time of 308 days
and a 2-year survival rate of 14% versus a median survival
time of 402 days and a 2-year survival rate of 26% for patients
with low wee1-expressing GBM (Figure 3E). wee1 expression
level was significantly associated with patient survival after
correction for confounding by age, gender, tumor recurrence,
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Figure 3. Gene Expression Levels Per Sample in Two GBM Array Data Sets and Quantitative PCR Data for the Nine Glioblastoma-Specific
Kinases
(A–C) Bar charts of expression intensities in arbitrary units for the nine glioblastoma-specific kinases in samples from twoGBMdata sets, (A) Kotliarov et al. (2006),
(B) Bredel et al. (2005), and (C) confirming quantitative RT-PCR data in human samples and GBM cell lines (see Table S5 for details and ordering of samples).
Each bar represents one sample. Color coding is according to grade. The solid line represents the mean of expression intensities for the normal tissue samples;
the dotted line represents the threshold for overexpression (see Supplemental Experimental Procedures).
(D) Immunohistochemical analysis of WEE1 in GBMs and non-neoplastic brain tissues. Scale bar represents 200 mm.
(E) Kaplan-Meier survival curves of GBM patients divided on basis of wee1 expression, red indicates high and black indicates low wee1 expression.
See also Figure S2 and Tables S5–S7.
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WEE1 Protects GBM against Mitotic Catastropheand prior treatment modalities, in a multivariate Cox propor-
tional-hazards regression model (hazard ratio: 0.69, 95%
confidence interval: 0.53–0.89, p = 0.0047 and Table S7).
Inhibition of WEE1 Abrogates the G2 Checkpoint
and Sensitizes GBM Cells to TMZ and IR In Vitro
After DNA damage induction, GBM cells mainly arrest in the G2
phase, due to an impaired G1 checkpoint (Hirose et al., 2001).
Indeed, U251MG GBM cells arrested in the G2 phase after IR
and TMZ treatment (Figures 4A and 4C). We then focused on
the role of WEE1 in the G2 checkpoint activation in response to
DNA damage. To specifically inhibit WEE1 function, we trans-
fected GBM cells with siRNA directed against the wee1 mRNA.
As determined by quantitative RT-PCR, the wee1 siRNA
efficiently knocked down wee1 mRNA levels, as compared to
nontargeting control siRNA (Figure S3A). After 48 hr the trans-
fected cells were either exposed to 6 Gray (Gy) of IR or treated
with 100 mMTMZ and 16 hr later cell-cycle distributionwasmoni-
tored by fluorescence activated cell sorting. DNA content was
monitored by propidium iodide staining and phospho-histone-
H3 staining was used as an indicator of mitotic entry. Knock
down of wee1 resulted in significant abrogation of the IR- andCanTMZ-induced G2 arrest and decrease in the amount of mitotic
cells (Figures 4A and 4C and Figures S3B and S3C). Similar abro-
gation of the DNA damage-induced arrest in U251MG cells was
achieved by using the WEE1 inhibitor PD0166285 (Wang et al.,
2001) (Figures 4A and4C, Figure S3D, and Figure S4E). Compar-
ative cell-cycle results were obtained using additional estab-
lished GBM cell lines (U118MG, U87MG, U373MG) and primary
GBM cells (VU147, VU148, E98) (Figures S3D and S3E). These
results indicate that WEE1 is a major determinant of the DNA
damage-inducedG2 arrest in GBMcells. Importantly, no adverse
effects of WEE1 inhibition on cell cycle were observed in primary
human fibroblasts and astrocytes, showing no loss of G1 arrest
after exposure to IR or TMZ in the presence or absence of WEE1
inhibitor or siRNA against wee1 (Figure 4B and Figures S3D and
S3E). Furthermore, no effects of PD0166285 on fibroblasts and
astrocytes were observed by WST-1 cell viability measurements
and microscopical monitoring of cellular morphology (data not
shown). Inhibition of WEE1 also reduces phosphorylation of its
downstream substrate CDC2 (Figure 4D and Figure S3F). This
suggests that the inhibitory CDC2 phosphorylation is reduced
by inhibition of WEE1 and thereby the CDC2-mediated G2 arrest
is abolished in GBM cells.cer Cell 18, 244–257, September 14, 2010 ª2010 Elsevier Inc. 247
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Figure 4. Inhibition of WEE1 Abrogates the G2 Checkpoint and Enhances Chemo- and Radiation-Sensitivity In Vitro
(A) Cell-cycle analysis of U251MG GBM cells at 16 hr after treatment with 6 Gy of IR, 100 mM of TMZ, and 1 mM of PD0166285.
(B) Cell-cycle analysis of human primary fibroblasts at 16 hr after treatment.
(C) Quantitation of PHH3 expression in U251MG cells treated with WEE1 siRNA, WEE1 inhibitor, or nontreated.
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WEE1 Protects GBM against Mitotic CatastropheWe then investigated the effects of WEE1 inhibition on the
viability of cells treated with IR, TMZ, or both. wee1 silencing
by siRNA or WEE1 inhibition by PD0166285 had a significant
sensitizing effect in combination with 6 Gy of IR, 100 mM of
TMZ, or both (Figures 4E and 4F and Figure S3G). At concentra-
tions up to 1 mm, PD0166285 had no effects on the viability of
GBM cells in the absence of IR and TMZ (Figure 4E). In addition,
radiosensitizing effects of PD0166285 in GBM cells could be
measured by colony formation assay (Figure 4G), which corre-
lated with wee1 gene expression levels in the GBM cells.
U373MG cells with a fold change log2 wee1 expression (FC)
compared to six non-neoplastic brain samples of 13.0 (see
Figure 3C) showed the largest sensitization, with a sensitizing
enhancement ratio (SER) of 1.95, U251MG cells (FC: 9.1, SER:
1.73) and U118MG cells (FC: 9.2, SER: 1.45) showed interme-
diate sensitization, whereas U87MG cells (FC 5.2 that is within
the upper threshold for normal expression of FC 6.4 and SER
of 1.19) showed the least sensitization (Figure 3C and
Figure 4G). In contrast, no correlation was observed between
p53 mutation status and WEE1 inhibitor sensitivity in the GBM
cells analyzed here. However, U87 cells, which express wee1
mRNA levels within the normal range (Figure 3C and Figure 4G)
and express the wild-type p53 (Figure S3H), showed the least
PD0166285-mediated radiosensitization (Figure 4G). There
was no significant effect of PD0166285 on colony formation in
non-irradiated GBM cells.
A subpopulation of GBM cells, the so-called cancer stem-like
cells, has been described to be particularly resistant to chemo-
and radiotherapy (Bao et al., 2006; Liu et al., 2006). In silico
analysis using the ONCOMINE database (Rhodes et al., 2004)
showed that wee1 was overexpressed to an even higher extent
in a subpopulation of GBM cells cultured in neural basal medium
(Lee et al., 2006) (Figure S3I). GBM neurospheres formed by
such cells expressed CD133, Nestin, and SOX2 (Figure S3J),
putative GBM stem-like cell markers (Lee et al., 2006). Next,
the radiosensitizing effect of WEE1 inhibitor PD0166285 on pri-
mary GBM neurospheres was determined. GBM neurospheres
failed to respond to exposure to IR alone, confirming their radio-
resistance (Bao et al., 2006). Importantly, dramatic cell death
was measured when primary GBM neurospheres were exposed
to IR in the presence of PD0166285. Although GBM stem-like
cell markers are still subject of continuous debate (Chen et al.,
2010), we isolated primary CD133 positive and negative GBM
cells with high wee1 expression and intermediate wee1 expres-
sion, respectively, as determined by qRT-PCR (Figure S3I).
Subsequently we treated the sorted cells with 0.5 mM of
PD0166285 and 6 Gy of IR. After 4 days the radiation-resistant
CD133 positive GBM cells were efficiently killed as determined
by WST-1 cell viability assay (Figure 4H). These results suggest
that radiation resistance of GBM stem-like cell populations can
be overcome by WEE1 inhibition in vitro.(D) Western blot analysis of CDC2, phosphorylated CDC2, and b-actin in U251M
(E) Representative cell counts of U251MG GBM cells at 4 days after treatment.
(F) WST-1 viability analysis of U251MG cells at 4 days after treatment.
(G) Colony formation of U87MG, U251MG, U118MG, and U373MG, at 7–14 day
(H) WST-1 viability analysis of CD133 sorted primary GBM cells at 4 days after tre
indicate standard deviation. ***p < 0.001, t test.
See also Figure S3.
CanInhibition of WEE1 in Irradiated GBM Cells Leads
to Mitotic Catastrophe Due to Residual DNA Damage
After induction of DNAdamage,WEE1 activates and sustains the
G2 cell-cycle arrest until DNA damage is sufficiently repaired
(Rowley et al., 1992). Therefore, inhibition of WEE1 should
abrogate G2 arrest activation and result in increased amounts
of unrepaired DNA damage in cells prematurely entering mitosis.
To determine the effect of WEE1 inhibition on the rejoining of
double-strand breaks (DSBs) and on DSB-induced cell-cycle
arrest, we exposed GBM cells to IR in the presence or absence
of the WEE1 inhibitor. IR resulted in induction of DSBs as evi-
denced by formation of ionizing radiation-induced foci (IRIF) by
a DSB marker g-H2AX (Rogakou et al., 1999), and by repair
factors ATMp1981, MDC1, and MRE11 (Goldberg et al., 2003;
Lavin, 2007) (Figures 5A and 5B). Phase-contrast time-lapse
imaging of the U251MG cells at 10-min intervals showed that
IR induced a considerable delay in the onset of mitosis (Figures
5C and 5D). In contrast, cells irradiated in the presence of
PD0166285 failed to delay their mitotic entry (Figures 5C and
5D), in agreement with the role of WEE1 in activating and
maintaining the G2 arrest.
In the absence of a functional G2 arrest, irradiated GBM cells
may not be capable of repairing the DNA damage before
entering mitosis, leading to mitotic catastrophe. We irradiated
GBM cells and then time-lapse imaged the cells in the presence
or absence of WEE1 inhibitor (Movie S1). Cells were fixed and
stained for g-H2AX and MDC1 and analyzed for completion of
mitosis by fluorescence microscopy. Exposure to IR alone
resulted in only a few residual DSBs in the daughter cell nuclei,
indicating near-complete DSB repair before the cells entered
mitosis (Figures 5E and 5G). In contrast, cells irradiated in the
presence of WEE1 inhibitor presented their daughter cells with
considerable amount of unrepaired DSBs (Figures 5F and 5G).
Additionally, the presence of PD0166285 resulted in largely
fragmented nuclei of the daughter cells (Figure 5F and
Movie S1), indicative of mitotic catastrophe due to DNA frag-
ments devoid of centromeres, which can not be properly segre-
gated during mitosis (Loffler et al., 2006). Together, these results
support the concept that G2 abrogation by WEE1 inhibition
results in mitotic catastrophe due to unrepaired DSBs that
explains the radiosensitizing properties of the WEE1 inhibitor.
WEE1 Inhibition Enhances Radiosensitivity
in Orthotopic GBM Models
To compare the antitumor efficacy of short hairpin-mediated
wee1 knock down alone or in combination with IR in vivo, we first
used a bioluminescent orthotopic model of human U251-Fluc-
mCherry cells (U251-FM) (Candolfi et al., 2007). U251-FM cells
were transduced with lentivectors encoding a control shRNA
or a shRNA directed against wee1 (shWEE11702). First, the
efficiency of wee1 knock down and reduction of cell viability inG GBM cells at 16 hr after treatment.
s after treatment.
atment. Shown are averages of experiments carried out in triplicate, error bars
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Figure 5. Inhibition of WEE1 in Irradiated
GBM Cells Leads to Mitotic Catastrophe
(A andB) Immunofluorescence visualization of IRIF
in irradiated U251MG cells in triplicate. Cells were
exposed to 2 Gy, fixed 30 min later and stained for
(A) total DNA (blue), MDC1 (red) and ATMp1981
(green) and (B) total DNA (blue), MRE11 (red)
g-H2AX (green). Scale bar represents 5 mm.
(C) Quantitation of the percentage of cells that
entered mitosis during the first 24 hr of imaging
after sham-irradiation (Control) or exposure to
6 Gy in the presence or absence of 500 nM of
WEE1 inhibitor. At least 300 cells were scored
per data point.
(D) Distribution of the percentage of cells entering
mitosis from (C) in the different periods after
indicated treatment.
(E and F) Immunofluorescence analysis of IRIF in
postmitotic cells. Cells were exposed to 6 Gy,
imaged for 16 hr in the absence (E) or presence
(F) of 500 nM WEE1 inhibitor, fixed and stained
for total DNA (blue), MDC1 (red), and ATMp1981
(green). Postmitotic cells are indicated by circles.
Scale bar represents 10 mm.
(G) Quantitation of the number of IRIF in postmi-
totic cells treated as in (E) and (F). IRIF in at least
50 cells were scored per data point. Error bars
indicate standard deviation. ***p < 0.001, t test.
See also Movie S1.
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WEE1 Protects GBM against Mitotic Catastropheresponse to wee1 knock down after IR-mediated DNA damage
was determined in these cells (Figure S4A). Second, control or
shWEE1 transduced U251-FM cells were implanted in the brain
of nude mice. The growth of tumors was monitored weekly by
bioluminescence imaging. Two weeks after intracranial injection
of the transduced cells, 50% of the mice in each group were
exposed to a single dose of 6 Gy. In mice injected with U251-
FM cells expressing shControl strong tumor progression was
observed in both irradiated and non-irradiated groups at 6weeks
after injection of the cells (Figures 6A and 6B). Similarly, the
nonirradiated U251-FM-shWEE1 cells showed strong increase
in bioluminescence signal after 6 weeks, whereas mice injected
with U251-FM-shWEE1 cells showed significant tumor regres-
sion after IR at 6 weeks after injection (Figures 6A and 6B). Tumor
burden was markedly reduced in irradiated mice carrying
shWEE1 transduced cells (Figure 6C). Survival analysis showed
a significant (p = 0.001) advantage for combining irradiation with
wee1 knock down (Figure 6D). These results indicate that wee1
knockdown sensitizes U251-FM GBMs to IR in vivo.
To determine the pharmacological characteristics and anti-
tumor efficacy of PD0166285 on GBM outcome in vivo, we first
implanted GBM cells subcutaneously (SC) into nude mice and
determine the PD0166285 dosage sufficient to inhibit WEE1
activity in vivo. Mice were injected with various doses of
PD0166285 (0, 20, 100, 200, or 400 mM in 100 ml) 20 days after
tumor cells implantation. No adverse side effects were observed
at the concentrations used. Tumors were removed 24 hr later
and analyzed for inhibition of WEE1-mediated CDC2 phosphor-
ylation by western blotting (Figure S4B). A single injection of
20 mM of the WEE1 inhibitor considerably reduced the CDC2
phosphorylation and was used in further experiments. Next,
U251-FM human GBM cells were injected intracranially into250 Cancer Cell 18, 244–257, September 14, 2010 ª2010 Elsevier Innude mice. Mice with established GBMs were treated daily
with PD0166285 or phosphate buffer solution (PBS) control via
an intraperitoneal (IP) injection starting at day 14 after injection
of the GBM cells. At day 15, the mice were sham irradiated or
exposed to a single dose of 6 Gy. The results showed strong
tumor progression in both irradiated and non-irradiated mock
treated mice at 6 weeks after injection of the cells (Figures 6E
and 6F). Similarly, the non-irradiated PD0166285 treated mice
showed strong increase in tumor signal after 6 weeks. In
contrary, irradiatedmice treated with PD0166285 showed signif-
icant tumor regression 6 weeks after tumor injection (Figures 6E
and 6F). Additionally, tumor burdenwasmarkedly reduced in this
animal group (Figure 6G). Survival analysis showed a significant
(p = 0.001) advantage for combining irradiation with PD0166285
(Figure 6H). These results indicate that pharmacological target-
ing of WEE1 sensitizes U251-FM GBM tumors to IR in vivo.
To confirm these results in an independent orthotopic GBM
model we used the E98 mouse model (Claes et al., 2008)
because it displays a highly invasive phenotype characteristic
for human GBM. We verified that WEE1 protein was overex-
pressed in this model by immunohistochemistry on tumor
sections (Figure S5A). To improve tumor detection, the E98 cells
were transduced to stably express Fluc and mCherry (E98-FM).
To determine whether wee1 knock down by shRNAs caused
radiosensitization in vivo, E98-FM cells were transduced with
lentivectors encoding shControl, or shWEE11704 directed against
wee1. The efficiency of wee1 knock down and reduction of cell
viability in response to WEE1 knock down combined with IR
was verified in these cells (Figure S5B). We then stereotactically
injected E98-FM-shControl or E98-FM-shWEE1 cells into nude
mice. After 10 days the mice were divided into two treatment
groups, with and without IR. In line with the U251-FM model,c.
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Figure 6. In Vivo Analysis of WEE1 Inhibition in an Orthotopic U251-FM Mouse Model
(A) U251-FM cells stably expressing shWEE1 or shControl were injected intracranially. Themice were divided in two groups of which one was irradiated with 6Gy.
Representative bioluminescence imaging results are shown 2 and 6 weeks after cancer cell injections.
(B) Relative photon flux at 2 and 6 weeks after cancer cell injections.
(C) Representative mCherry images of the brain tumors after treatment. Size bar represents 200 mm.
(D) wee1 silencing enhances radiosensitivity in vivo, as depicted by survival curves (n = 5/group).
(E) U251-FM cells were injected intracranially, andmice were irradiated with 6Gy, and injected intraperitoneally with 500 ml of 20 mMof PD0166285 or PBS control
for 5 consecutive days. Representative bioluminescence imaging results are shown 2 and 6 weeks after cancer cell injections.
(F) Relative photon flux 2 and 6 weeks after cancer cell injections.
(G) Representative mCherry images of the brain tumors after treatment. Size bar represents 200 mm.
(H) PD0166285 enhances radiosensitivity in vivo, depicted is the survival of the mice (n = 5/group).
See also Figure S4.
Cancer Cell
WEE1 Protects GBM against Mitotic Catastrophe
Cancer Cell 18, 244–257, September 14, 2010 ª2010 Elsevier Inc. 251
1 week 3 weeks
D E
A C
Week 1
Week 3
- IR +IR
shCTRL shWEE11704
- IR +IR
B
shCTRL
shCTRL +IR
shWEE1
shWEE1 +IR
1.0
0.8
0.6
0.4
0.2
0.0
Su
rv
iv
a
l
0 10 20 30
Days
40
1.0
0.8
0.6
0.4
0.2
0
Su
rv
iva
l
Days
0 5 10 15 20 25
Control
PD0166285
PD0166285 + IR
IR
Control PD0166285 IR IR + PD0166285
Animal died
Figure 7. In Vivo Analysis of WEE1 Inhibition in an Invasive E98 GBM Mouse Model
(A) E98-FM cells stably expression shWEE1 or shControl were grown in the brains of nude mice. The mice were divided in two arms of which one was irradiated
with 3.5 Gy. Representative bioluminescence imaging results are shown 7 days and 3 weeks after onset of tumor growth.
(B) Relative photon flux at 7 days and 3 weeks after onset of tumor growth. (n = 4/group for control and n = 5 for IR treated).
(C) Survival curves of the mice in (B).
(D) E98 GBMs were grown in the brain of nude mice, irradiated with 8 Gy, and injected intraperitoneally with 500 ml of 20 mM of PD0166285 or PBS control for
5 consecutive days. Depicted are hematoxylin and eosin staining of irradiated E98 GBM tumors treated with PD0166285 or PBS control. Red lines indicate
nonsurvivors. Size bar represents 1000 mm.
(E) PD0166285 enhances radiosensitivity in vivo. Depicted is survival (n = 10/group), log rank p = 0.001.
See also Figure S5.
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showed markedly reduced tumor burden (Figures 7A and 7B),
and their survival was significantly prolonged as compared to
other treatment groups (Figure 7C).
Nextwedetermined thepharmacological effectsofPD0166285
in the E98 GBM model. In line with the U251-FM model, mice
treated with PD0166285 and irradiation showed considerably
reduced tumor burden (Figure 7D) and their survival was signifi-
cantly prolonged as compared to other treatment groups
(Figure 7E). Both groups of mice subjected to IR or PD0166285
monotherapy showed intermediate results. On day 23, all remain-
ing mice were sacrificed and histological analysis of the brains
wasperformed. Importantly, E98GBMtumorswere undetectable
in any mice that were alive after the IR/PD0166285 combination
treatment. This could not be explained by lack of tumor growth
before the treatment, given the effects in mice without treatment
and clear changes of brain structure indicating that tumor growth
had in fact occurred (Figure 7C). The sham-treated mice and252 Cancer Cell 18, 244–257, September 14, 2010 ª2010 Elsevier Inthe mice treated with IR or WEE1 inhibitor alone, showed typical
infiltrative GBM growth, although a significant beneficial effect
of irradiation was observed (Figure 7D). This in vivo therapeutic
response to PD0166285 in combination with irradiation and the
lackof adverse sideeffects underline thepotential ofWEE1kinase
inhibition in GBM treatment.Analysis of ‘‘Push’’ and ‘‘Pull’’ Kinase Inhibitors
on DNA Damage Repair in GBM Cells
WEE1 is part of an intricate network of kinases and phospha-
tases regulating the G2 checkpoint (Figure 8A) (Elder et al.,
2001; Katayama et al., 2005; Kim and Ferrell, 2007; O’Connell
et al., 1997; van Vugt et al., 2004; Watanabe et al., 2004). Several
kinase inhibitors were developed to ‘‘pull back’’ the cancer cells
during cell-cycle arrest, aiming at stagnation of tumor growth,
examples include inhibitors targeting PLK1 and AKT. In contrast,
other kinase inhibitors, such as those targeting CHK1 andWEE1,c.
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Figure 8. Analysis of the Effects of G2 Checkpoint Prolongation and Abrogation on DNA Repair and on DNA Damage-Induced Mitotic
Catastrophe in GBM Cells
(A) Schematic overview of kinases, phosphatases, and inhibitors involved in theG2 cell-cycle arrest. Kinases (green) and phosphatases (red) and their interactions
are indicated.
(B) Western blot analysis of CDC2, CDC2py15, WEE1, and b-actin, in control or irradiated U251MG cells treated with the indicated inhibitors for 6 hr.
(C) Cell-cycle analysis of irradiated or non-irradiated U251MG cells treated with different inhibitors for 6 hr. At 16 hr after IR the cells were analyzed by
fluorescence-activated cell sorting.
(D) WST-1 viability analysis of irradiated or non-irradiated U251MG cells treated with different inhibitors at 4 days after treatment.
(E) Immunofluorescence analysis of IRIF in postmitotic cells. Cells were exposed to 6 Gy, imaged for 16 hr in standard medium or in medium containing one of the
following kinase inhibitors, CHK1 (200 nM),WEE1 (500 nM), PLK1 (100 nM), AKT (50 mM), fixed and stained for total DNA (blue), MDC1 (red), and ATMp1981 (green).
Inhibitors of AKT and PLK1 were removed from the medium at 6 hr after irradiation because continuous exposure completely abrogated cell division. Postmitotic
cells are indicated by ellipsoids. Scale bar represents 5 mm.
(F) Quantitation of the number of IRIF in postmitotic cells treated as in (A). IRIF in at least 50 cells were scored per data point.
(G) Quantitation of the percentage of cells treated as in (A) that entered mitosis during the first 20 hr of imaging. At least 300 cells were scored per data point.
Experiments were carried out in triplicate. Error bars represent standard deviation. ***p < 0.001, t test.
See also Movie S2.
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mitosis.
We first determined the effect of the selected inhibitors on
CDC2 phosphorylation by western blotting (Figure 8B). Irradia-Cantion of GBM cells resulted in increased phosphorylation of
CDC2, which was not affected by inhibitors of PLK1 or AKT,
but significantly reduced by inhibitors of CHK1 and WEE1
(Figure 8B). We then analyzed the effects of these inhibitors oncer Cell 18, 244–257, September 14, 2010 ª2010 Elsevier Inc. 253
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and 8D). The inhibition of CHK1 and WEE1 kinases resulted in
abrogation of IR-induced G2 arrest (Figure 8C). In contrast, the
inhibitors of PLK1 and AKT increased the fraction of cells in
the G2 phase as compared to cells treated with IR alone (Fig-
ure 8C). We then determined the effects of the different kinase
inhibitors on radiosensitivity of GBM cells (Figure 8D). A signifi-
cant reduction in viability was observed when cells were irradi-
ated in the presence of CHK1 and WEE1 inhibitors. In marked
contrast, inhibition of AKT failed to increase sensitivity of GBM
cells to IR and inhibition of PLK1 exhibited radioprotective
properties.
G2 checkpoint abrogation by WEE1 inhibition resulted in
mitotic catastrophe due to unrepaired DSBs (Figure 5 andMovie
S1). Similar results were obtained when GBM cells were irradi-
ated in the presence of CHK1 inhibitor (Movie S2). In contrast,
incubation of cells in the presence of inhibitors of PLK1 and
AKT for 6 hr after irradiation failed to affect the mitotic entry, as
compared to cells exposed to IR alone (Movie S2).
We then assessed the amount of residual DNA damage in cells
that underwent mitosis after exposure to IR and the different
inhibitors (Figures 8E and 8F). Daughter cells originating from
cells irradiated in the presence of CHK1 and WEE1 inhibitors
contained a large number of unrepaired DSBs indicating incom-
plete DNA repair (Figures 8E and 8F). In contrast, the combina-
tion of IR with PLK1 and AKT inhibitors did not result in an
increase of unrepaired DSBs in the daughter cells, suggesting
that DNA repair was near-complete before the cells entered
mitosis (Figures 8E and 8F). In agreement with the effects of
inhibitors of PLK1, AKT, CHK1, and WEE1 on CDC2 phosphory-
lation (Figure 8B), a considerable delay in the onset of mitosis
was measured in the GBM cells treated with inhibitors of PLK1
and AKT—the ‘‘cell-cycle pullers’’ (Figure 8G and Movie S2). In
contrast, cells irradiated in the presence of inhibitors of CHK1
and WEE1—the cell-cycle pushers—failed to delay the mitotic
entry (Figure 8G and Movie S2). Thus, the strategy assuming
abrogation rather than prolongation of the G2 checkpoint may
be more effective in increasing sensitivity of GBM cells to DNA
damage in vitro.
DISCUSSION
Three main findings are put forward by the present study. First,
we have identified a GBM-specific kinase expression profile,
providing a list of substantially and frequently overexpressed
kinases involved in GBM signaling pathways. In addition, anal-
ysis of other cancer kinase expression profiles verified previously
known overexpressed kinases and provided a platform for
retrieval of kinase treatment targets. Implications consist of
a further advancement of our understanding of oncogenic kinase
signaling and a possibility for rational planning of future kinase
inhibitory strategies, although, clearly, kinase overexpression is
not the only mode of deregulation. Indeed WEE1 activity has
been described to be regulated by protein ubiquitination, proteo-
lytic degradation, and phosphorylation (Watanabe et al., 2004;
Rothblum-Oviatt et al., 2001; Kim and Ferrell, 2007; van Vugt
et al., 2004; O’Connell et al., 1997; Katayama et al., 2005;
McGowan and Russell, 1993). Second, the list of differentially
expressed kinases in GBM was spearheaded by wee1 that we254 Cancer Cell 18, 244–257, September 14, 2010 ª2010 Elsevier Innow present as a potential treatment target. Third, we postulate
that the profound overexpression of wee1 in treatment-resistant
GBM contributes to efficient DNA repair at the G2 checkpoint.
Moreover, the subpopulation of so-called GBM stem-like cells,
that are more resistant to irradiation and chemotherapeutics
(Bao et al., 2006; Liu et al., 2006) and were described to reside
in a low proliferative state in vascular niches (Calabrese et al.,
2007), were sensitized by WEE1 inhibition, indicating a major
role for WEE1 in conferring radio-resistance of these cells. Our
findings support the concept that cancer cells with sub-lethal
DNA damage induced by conventional radio- and chemotherapy
can be catastrophically pushed into premature mitosis by
inhibition of WEE1 activity.
The kinases identified as most frequently overexpressed are
often involved in cell-cycle regulation. DNA damaging agents,
such as those used during standard GBM treatment, induce
arrest in G1 or G2 phases (Iliakis et al., 2003; Hirose et al.,
2001). These arrests are brought about by checkpoint mecha-
nisms that provide time for repair of sub-lethal DNA damage
before resuming the cell cycle (Branzei and Foiani, 2008).
Due to defective TP53 signaling, many cancer cells lack the
functional G1 arrest and depend to a greater extent on the G2
checkpoint in response to DNA damage (Kawabe, 2004). There-
fore, abrogation of the G2 checkpoint, inducing premature
mitotic entry and subsequent cell death, has emerged as a
potential therapeutic strategy (Kawabe, 2004; Vogelstein et al.,
2000). Inhibitors of theG2 checkpoint activation such as caffeine,
pentoxifylline and the CHK1 kinase inhibitor UCN-01 have been
shown to push cells containing residual unrepaired DNA damage
into premature mitosis, resulting in sensitization to DNA-
damaging agents (Reinhardt et al., 2007; Russell et al., 1996;
Sarkaria et al., 1999).
WEE1 kinase is involved in the G2 checkpoint control by acting
directly on CDC2, the driving force for G2 progression (McGowan
and Russell, 1993; O’Connell et al., 1997; Parker and Piwnica-
Worms, 1992; Rowley et al., 1992; Russell and Nurse, 1987).
WEE1 was identified through genetic studies of cell size control
and cell-cycle progression in Schizosaccharomyces pombe
(Nurse, 1975). Subsequent work established WEE1 as a tyrosine
kinase belonging to the Ser/Thr family of protein kinases (Russell
and Nurse, 1987; Featherstone and Russell, 1991). WEE1 cata-
lyzes the inhibitory tyrosine (Y15) phosphorylation of CDC2/
cyclin B kinase, so that the G2/M transition is prevented (Russell
and Nurse, 1987; Parker and Piwnica-Worms, 1992; McGowan
and Russell, 1993).
From several arguments it seems reasonable that inhibition of
WEE1 can be a safe therapeutic strategy. First, many cancer
cells, and GBM cells in particular, harbor p53 mutations, which
render these cells more dependent on the G2 checkpoint
(Kawabe, 2004; Wang et al., 2001; Li et al., 2002). Second,
inhibition of WEE1 affected neither normal human fibroblasts
nor astrocytes in terms of DNA cytometry and cellular
morphology. Third, no acute adverse effects were detected in
mice after high dose injection of WEE1 inhibitor in our dose-
effect experiment.
Deregulation of the TP53 pathway occurs in 87% of GBMs by
various mechanisms, including cdkn2a deletion or mutation,
mdm2 and mdm4 amplification and P53 deletion or mutation
(The Cancer Genome Atlas Research Network, 2008). Althoughc.
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to be dependent on TP53 activity (Wang et al., 2001; Li et al.,
2002), we did not see such a correlation. However, a functional
G1 arrest with concurrent wild-type TP53 expression in fibro-
blasts and astrocytes is likely to explain the absence of cell death
after induction of DNA damage by IR and WEE1 inhibition in
these non-neoplastic cells, whereas the level of WEE1 inhibitor
sensitivity in G2-dependent GBM cells depends on the level of
wee1 expression.
Overexpression of wee1 was described previously for several
types of cancer. The expression of wee1 was found to be upre-
gulated in poorly differentiated and more advanced hepatocel-
lular carcinoma (Masaki et al., 2003). Further, WEE1 inhibition
has been suggested as anticancer therapy based on findings
in cell lines from melanoma, cervical carcinoma, colon carci-
noma, and ovarian carcinoma (Hashimoto et al., 2006; Wang
et al., 2001; Wang et al., 2004). Of note, our stringent in silico
analysis on data of primary normal versus cancer tissues indi-
cates overexpression of wee1 in most cancer types (for 27 of
35 data sets; Figure 2A). However, the top-rankingwee1 expres-
sion levels in GBM were not reached by any of the other cancer
types analyzed. Nonsmall cell lung carcinoma, (non-)seminoma,
and colon carcinoma also showed high wee1mRNA expression
levels, whereas the other cancer types mostly showedmoderate
overexpression as compared to the relevant non-neoplastic
control tissues.
Intriguingly, monotherapeutic inhibition of WEE1 also resulted
in a beneficial response of GBMs in mice. An explanation for this
effect can be that DNA damage in GBM cells is not only induced
by cancer therapy but that the DNA integrity of these cells is
continuously threatened by inherent genomic instability (The
Cancer Genome Atlas Research Network, 2008).
Like the PLK1 and AKT inhibitors, many of the small molecule
inhibitors or antibodies have been developed to restrain cancer
growth by halting cell replication. Efficacy of this strategy has
been demonstrated (Agulnik et al., 2007; Lynch et al., 2004;
Ravaud et al., 2008; Vieth et al., 2005; Zhang et al., 2009).
However, results of the present study stress the importance of
proper treatment timing when combining such agents with
DNA damage-induction. Inhibition of CHK1 and WEE1 has clear
radiosensitizing effects, suggesting that promoting, rather than
halting the cell-cycle progression should be considered as radio-
sensitizing strategy in glioblastoma. Effects of CHK1 inhibitors
were analyzed in various tumor models (Bao et al., 2006; Hirose
et al., 2001; Reinhardt et al., 2007; Sidi et al., 2008), revealing
significant toxicity to non-neoplastic cells, which might be
explained by involvement of CHK1 in activation of both the G2
and the G1 cell-cycle checkpoints (Kortmansky et al., 2005;
Shieh et al., 2000). Here we show that inhibition of WEE1 by
PD0166285 does not result in measurable toxic side effects at
therapeutically relevant doses in mice, which may be explained
by its G2-specific cell-cycle interference.
In summary, we revealed a dominant role of the WEE1 kinase
in controlling the G2 checkpoint in GBM and designated this
protein as a possible target in treatment-resistant glioblastoma.
We showed that GBM cells can be pushed into mitotic catas-
trophe byWEE1 inhibition after DNA damaging radio- or chemo-
therapy. Our results suggest that inhibition of WEE1 activity may
prove effective in enhancing GBM treatment.CanEXPERIMENTAL PROCEDURES
Compounds
The WEE1 inhibitor PD0166285 (Pfizer, Ann Arbor, MI) was diluted in PBS.
Inhibitors of PLK1 (BI-2536) and PI3K/AKT (LY-294002) (Axon Medchem,
Groningen, the Netherlands) were dissolved in dimethyl sulfoxide (DMSO)
(Sigma-Aldrich, St. Louis, MO). Inhibitors (Calbiochem, La Jolla, CA) were
diluted in DMSO. Temozolomide (Schering Plough, Kenilworth, NJ) was
diluted in DMSO, prepared freshly each time, and used at a final concentration
of 100 mM.
Tissue Samples and Cells
Surgical samples were obtained from four glioma patients with World Health
Organization (WHO) grade 2, five patients with WHO grade 3, and 14 patients
with glioblastoma multiforme (GBM) after informed consent and approval by
the Hospital Medical Ethical Committee (Table S5). Furthermore, 16 GBM
cell lines were included (Table S6). Cancer stem-like cell cultures were derived
from patients with GBM (VUmc, the Netherlands). The stem-like cells were
isolated and cultured as described elsewhere (Lee et al., 2006).
RNA Isolation and Interference
Total RNA was isolated using the RNAeasy kit (QIAGEN, Valencia, CA),
according the manufacturer’s protocol. The quality and quantity of the RNA
was analyzed by photospectrometry. RNA interference was carried out by
transfecting siRNAs (50 nM, QIAGEN). Lentivectors encoding validated
wee1 shRNAs (Sigma-Aldrich; WEE1 Reference Sequence NM_003390;
shRNA reference numbers TRCN0000001702 and TRCN0000001704,
referred to as shWEE11702 and shWEE11704, respectively), were produced
and used to transduce U251-FM and E98-FM cells. The SHC002 scrambled
shRNA construct (Sigma-Aldrich) was used as a negative control.
Immunofluorescence Staining, Immunohistochemistry,
and Western Blotting
Cell cultures were fixed using 2% paraformaldehyde in PBS for 15min at room
temperature (RT), permeabilized using 1% Triton X-100 in PBS for 30 min at
RT. The following antibodies were used: rabbit anti-MDC1 (A300-051A, Bethyl
Laboratories), mouse anti-g-H2AX (05-636, Millipore), rabbit anti-MRE11 (de
Jager et al., 2001), mouse anti-ATMpthr1981 (4526S, Cell Signaling Technology)
goat anti-mouse-Cy3 (115-165-166), and goat anti-rabbit-FITC (111-095-144)
(Jackson Immunoresearch). Immunohistochemical staining was carried out as
described previously (Yoshida et al., 2004). Western blotting was carried out
with the following primary antibodies: mouse anti-WEE1 (1:1,000, Santa
Cruz Biotechnology, Santa Cruz, CA), mouse anti-CDC2 (1:1000, Abcam),
rabbit anti-CDC2pY15 (1:2000, Abcam), mouse anti-b-actin (1:5000, Santa
Cruz), and mouse anti-p53 (1:1000, NeoMarkers).
Irradiation, Live-Cell Imaging, and Fluorescence Imaging
Approximately 1.5 3 105 cells were plated in 25 cm2 culture flasks and incu-
bated for 24 hr in standard medium. Next, required inhibitors were added for
30 min and cells were exposed to gamma-irradiation. Next, cells were
mounted under Leica IRBE inverted fluorescence microscope (Leica
Microsystems) in an incubator with adjustable CO2 concentration, at 37
C.
Positions of imaged cells were saved using custom-written software. Phase-
contrast, time-lapse movies were acquired at 10-min intervals for required
period of time. If required, after imaging, cells were fixed, stained for indicated
proteins, and imaged using fluorescence microscopy.
In Vivo Analysis Using the U251 and E98 Orthotopic
GBM Mouse Models
All experiments on mice were approved by the Subcommittee on Research
Animal Care at Radboud University (Nijmegen, the Netherlands), VUmc (Am-
sterdam, the Netherlands), or Massachusetts General Hospital (Boston, MA),
and were carried out in accordance to their guidelines and regulations. E98
tumor fragments (8 mm3) were grafted subcutaneously in the flank of Balb/C
nude mice (n = 10). For the experiments with the orthotopic tumors,
U251MG and E98 cells were transduced to express Fluc and mCherry, to
generate U251-FM and E98-FM cells. One million cells were injected intracra-
nially. Starting at 12 days after tumor inoculation, mice received the WEE1cer Cell 18, 244–257, September 14, 2010 ª2010 Elsevier Inc. 255
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WEE1 Protects GBM against Mitotic Catastropheinhibitor PD0166285 via intraperitoneal injections (500 ml of a 20 mM solution
diluted in NaCl) or vehicle for 5 consecutive days. On days 10–15, mice were
irradiated with a single dose of irradiation.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, seven tables, Supplemental
Experimental Procedures, and two movies and can be found with this article
online at doi:10.1016/j.ccr.2010.08.011.
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